Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 0.79 |
| ▸ | ERBB2 | P04626 | 15/20 | 0.79 |
| ▸ | ABL1 | P00519 | 4/20 | 0.79 |
| ▸ | INSR | P06213 | 4/20 | 0.79 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.79 |
| ▸ | CDK2 | P24941 | 4/20 | 0.79 |
| ▸ | PLK1 | P53350 | 3/20 | 0.79 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.79 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.79 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.79 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.79 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.79 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.79 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.79 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.79 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.79 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.79 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.79 |
| ▸ | MEN1 | O00255 | 1/20 | 0.71 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29387336 | 1.00 | EGFR (0.79) | EGFRERBB2ABL1INSRPDGFRB | |
| Hydrochloric Acid SCHEMBL2511570 | 0.99 | EGFR (0.78) | EGFRERBB2ABL1INSRPDGFRB | |
| SCHEMBL1448581 | 0.94 | EGFR (0.77) | EGFRERBB2ABL1INSRPDGFRB | |
| SCHEMBL12727551 | 0.93 | EGFR (0.69) | EGFRERBB2ABL1INSRPDGFRB | |
| SCHEMBL15000311 | 0.92 | EGFR (0.68) | EGFRERBB2ABL1INSRPDGFRB | |
| SCHEMBL3326173 | 0.92 | EGFR (0.68) | EGFRERBB2ABL1INSRPDGFRB | |
| SCHEMBL3009979 | 0.91 | EGFR (0.69) | EGFRERBB2ABL1INSRPDGFRB | |
| SCHEMBL142111 | 0.91 | EGFR (0.68) | EGFRERBB2ABL1INSRPDGFRB | |
| SCHEMBL12719625 | 0.91 | EGFR (0.66) | EGFRERBB2ABL1INSRPDGFRB | |
| SCHEMBL13966850 | 0.91 | EGFR (0.68) | EGFRERBB2ABL1INSRPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 256 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118184927-A | Polymer material carrier, preparation method thereof, polymer material carrier supported palladium nanoparticle and application | 河北科技大学 | 2024-06-14 | — | — | CN | claimed |
| US-20120295928-A1 | METHODS FOR DETECTING AND REDUCING IMPURITIES OF LAPATINIB AND SALTS THEREOF | F.I.S. FABBRICA ITALIANA SINTETICI S.P.A. (IT) | 2012-11-22 | — | — | US | claimed |
| EP-2489661-A1 | Impurity of lapatinib and salts thereof | F.I.S. Fabbrica Italiana Sintetici S.p.A. (IT) | 2012-08-22 | — | — | EP | claimed |
| EP-1454907-B1 | Quninazoline and pyridopyrimidine derivatives | GLAXO GROUP LTD (GB) | 2008-12-17 | — | — | EP | claimed |
| US-20080058519-A1 | QUINAZOLINE DITOSYLATE SALT COMPOUNDS | LEO OSPREY LIMITED (GB) | 2008-03-06 | — | — | US | claimed |
| US-7109333-B2 | Heterocyclic compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2006-09-19 | — | — | US | claimed |
| US-20050130996-A1 | Heterocyclic compounds | NOVARTIS AG (CH) | 2005-06-16 | — | — | US | claimed |
| EP-1454907-A1 | Quninazoline and pyridopyrmidine derivatives | Glaxo Group Limited (GB) | 2004-09-08 | — | — | EP | claimed |
| US-12594275-B2 | Immunophilin binding agents and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-04-07 | — | — | US | disclosed |
| US-12558356-B2 | Immunophilin binding agents and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-02-24 | — | — | US | disclosed |
| US-20250108052-A1 | IMMUNOPHILIN BINDING AGENTS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-04-03 | — | — | US | disclosed |
| CN-118184927-A | Polymer material carrier, preparation method thereof, polymer material carrier supported palladium nanoparticle and application | 河北科技大学 | 2024-06-14 | — | — | CN | disclosed |
| US-20230063768-A1 | IMMUNOPHILIN BINDING AGENTS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-03-02 | — | — | US | disclosed |
| US-20230063768-A1 | IMMUNOPHILIN BINDING AGENTS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-03-02 | — | — | US | disclosed |
| WO-2002056912-A2 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF CANCER CONTAINING A 4-QUINAZOLINEAMINE AND ANOTHER ANTI-NEOPLASTIC AGENT | GLAXO GROUP LIMITED (GB) | 2002-07-25 | — | — | WO | disclosed |
| EP-1192151-A1 | ANILINOQUINAZOLINES AS PROTEIN TYROSINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2002-04-03 | — | — | EP | disclosed |
| WO-2002002552-A1 | QUINAZOLINE DITOSYLATE SALT COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2002-01-10 | — | — | WO | disclosed |
| WO-2001004111-A1 | ANILINOQUINAZOLINES AS PROTEIN TYROSINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2001-01-18 | — | — | WO | disclosed |
| EP-1047694-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2000-11-02 | — | — | EP | disclosed |
| WO-1999035146-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 1999-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295928-A1 | METHODS FOR DETECTING AND REDUCING IMPURITIES OF LAPATINIB AND SALTS THEREOF | SRMS, ABL1, ERBB2 | EGFR 5/4885ERBB2 3/4885ABL1 2/4885 |
| US-20080058519-A1 | QUINAZOLINE DITOSYLATE SALT COMPOUNDS | ERBB4, ABL1, ERBB2 | EGFR 64/4885ERBB2 3/4885ABL1 2/4885 |
| US-20230063768-A1 | IMMUNOPHILIN BINDING AGENTS AND USES THEREOF | PMP22, MAG, FABP7 | EGFR 3726/4885ERBB2 3924/4885ABL1 4111/4885 |
| US-12594275-B2 | Immunophilin binding agents and uses thereof | CCR1, CCRL2, CCR3 | EGFR 2717/4885ERBB2 1975/4885ABL1 4373/4885 |
| US-20050130996-A1 | Heterocyclic compounds | CCNH, SDHA, CYP1A2 | EGFR 3748/4885ERBB2 3150/4885ABL1 1065/4885 |
| US-20250108052-A1 | IMMUNOPHILIN BINDING AGENTS AND USES THEREOF | SERPINA6, SELPLG, FABP7 | EGFR 3638/4885ERBB2 3961/4885ABL1 3639/4885 |
| US-12558356-B2 | Immunophilin binding agents and uses thereof | CCRL2, CFB, CCR3 | EGFR 1974/4885ERBB2 1701/4885ABL1 3756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.